Miragen Therapeutics (MGEN) is Initiated by Wedbush to “Outperform”

Miragen Therapeutics (MGEN) was Initiated by Wedbush to “Outperform” and the brokerage firm has set the Price Target at $19. Wedbush advised their Clients and Investors in a research report released on Feb 21, 2017.

Miragen Therapeutics

Add Comment